The efficacy of early treatment with convalescent plasma in patients with COVID-19 is debated. Nothing is known about the potential effect of other plasma components other than anti-SARS-CoV-2 antibodies.
Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial
Ciccone, Giovannino;Guaschino, Roberto;Calcagno, Andrea;
2022-01-01
Abstract
The efficacy of early treatment with convalescent plasma in patients with COVID-19 is debated. Nothing is known about the potential effect of other plasma components other than anti-SARS-CoV-2 antibodies.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
222 - Convalescent - Manzini.pdf
file disponibile solo agli amministratori
Licenza:
DRM non definito
Dimensione
997.75 kB
Formato
Adobe PDF
|
997.75 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
